Identification

Name
Travoprost
Accession Number
DB00287  (APRD01271)
Type
Small Molecule
Groups
Approved
Description

Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin F2alpha analogue. [Wikipedia]

Structure
Thumb
Synonyms
  • Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1e,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
  • Travoprost
  • Travoprostum
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IzbaSolution0.003 %OphthalmicNovartis2017-02-06Not applicableCanada
IzbaSolution / drops30 μg/mlOphthalmicAlcon, Inc.2014-02-20Not applicableEu
IzbaSolution / drops30 μg/mlOphthalmicAlcon, Inc.2014-02-20Not applicableEu
Sandoz TravoprostSolution0.004 %OphthalmicSandoz Canada Incorporated2014-08-15Not applicableCanada
TravatanSolution / drops40 μg/mlOphthalmicAlcon, Inc.2001-11-27Not applicableEu
TravatanSolution / drops40 μg/mlOphthalmicAlcon, Inc.2001-11-27Not applicableEu
TravatanSolution0.004 %OphthalmicAlcon, Inc.2001-11-132010-11-16Canada
TravatanSolution / drops40 μg/mlOphthalmicAlcon, Inc.2001-11-27Not applicableEu
TravatanSolution / drops40 μg/mlOphthalmicAlcon, Inc.2001-11-27Not applicableEu
Travatan ZSolution.04 mg/mLOphthalmicPhysicians Total Care, Inc.2008-12-09Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-travoprost ZSolution0.004 %OphthalmicApotex Corporation2014-08-14Not applicableCanada
Mylan-travoprost ZSolution0.004 %OphthalmicMylan PharmaceuticalsNot applicableNot applicableCanada
PMS-travoprost ZSolution0.004 %OphthalmicPharmascience IncNot applicableNot applicableCanada
Teva-travoprost Z Ophthalmic SolutionSolution0.004 %OphthalmicTeva2014-08-18Not applicableCanada
Travoprost Ophthalmic Solution 0.004%Solution.04 mg/mLOphthalmicPar Pharmaceutical2013-04-152019-10-31Us
International/Other Brands
Travatan / Travatan Z / Travo-Z
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-travoprost-timopTravoprost (0.004 %) + Timolol (0.5 %)SolutionOphthalmicApotex CorporationNot applicableNot applicableCanada
Duotrav PqTravoprost (0.004 %) + Timolol (0.5 %)SolutionOphthalmicNovartis2006-04-11Not applicableCanada
Sandoz Travoprost / Timolol PqTravoprost (0.004 %) + Timolol (0.5 %)SolutionOphthalmicSandoz Canada IncorporatedNot applicableNot applicableCanada
Categories
UNII
WJ68R08KX9
CAS number
157283-68-6
Weight
Average: 500.5477
Monoisotopic: 500.238573467
Chemical Formula
C26H35F3O6
InChI Key
MKPLKVHSHYCHOC-AHTXBMBWSA-N
InChI
InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
IUPAC Name
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate
SMILES
CC(C)OC(=O)CCC\C=C/C[[email protected]]1[[email protected]@H](O)C[[email protected]@H](O)[[email protected]@H]1\C=C\[[email protected]@H](O)COC1=CC=CC(=C1)C(F)(F)F

Pharmacology

Indication

Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.

Structured Indications
Pharmacodynamics

Travoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor.

Mechanism of action

Travoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.

TargetActionsOrganism
AProstaglandin F2-alpha receptor
agonist
Human
Absorption

Systemically absorbed when administered to the eye.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the α(carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond.

Route of elimination

Less than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid.

Half life

Terminal elimination half-life of travoprost free acid is 45 minutes.

Clearance
Not Available
Toxicity

Symptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Limonene, (+)-.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Travoprost.Experimental
AcebutololTravoprost may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Adapalene.Approved
AlclofenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Travoprost.Approved, Investigational
AliskirenTravoprost may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Alminoprofen.Experimental
AlprenololTravoprost may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanTravoprost may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineTravoprost may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineTravoprost may increase the hypotensive activities of Amlodipine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Travoprost.Approved, Illicit
AndrographolideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Andrographolide.Investigational
AnisodamineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Travoprost can be decreased when used in combination with Apocynin.Investigational
ApremilastThe therapeutic efficacy of Travoprost can be decreased when used in combination with Apremilast.Approved, Investigational
AtenololTravoprost may increase the hypotensive activities of Atenolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Travoprost.Approved
AzapropazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Balsalazide.Approved, Investigational
BarnidipineTravoprost may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilTravoprost may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideTravoprost may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Travoprost.Withdrawn
BenorilateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Benzydamine.Approved
BepridilTravoprost may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Travoprost.Approved
BethanidineBethanidine may increase the hypotensive activities of Travoprost.Approved
BevoniumThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Travoprost.Experimental
BimatoprostTravoprost may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololTravoprost may increase the hypotensive activities of Bisoprolol.Approved
BosentanBosentan may increase the hypotensive activities of Travoprost.Approved, Investigational
BQ-123Travoprost may increase the hypotensive activities of BQ-123.Investigational
BretyliumTravoprost may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Travoprost.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Travoprost.Experimental
BromfenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bucillamine.Investigational
BufexamacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bufexamac.Experimental
BumadizoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bumadizone.Experimental
BupranololTravoprost may increase the hypotensive activities of Bupranolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Travoprost.Experimental
CafedrineTravoprost may increase the hypotensive activities of Cafedrine.Investigational
CandesartanTravoprost may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilTravoprost may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilTravoprost may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilTravoprost may increase the hypotensive activities of Captopril.Approved
Carbaspirin calciumThe therapeutic efficacy of Travoprost can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Travoprost.Withdrawn
CarprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololTravoprost may increase the hypotensive activities of Carteolol.Approved
CarvedilolTravoprost may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololTravoprost may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideTravoprost may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneTravoprost may increase the hypotensive activities of Chlorthalidone.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CicletanineTravoprost may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilTravoprost may increase the hypotensive activities of Cilazapril.Approved
ClonidineClonidine may increase the hypotensive activities of Travoprost.Approved
ClonixinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Clonixin.Approved
CloranololTravoprost may increase the hypotensive activities of Cloranolol.Experimental
CryptenamineTravoprost may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe therapeutic efficacy of Travoprost can be decreased when used in combination with Curcumin.Investigational
CyclopenthiazideTravoprost may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideTravoprost may increase the hypotensive activities of Cyclothiazide.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Travoprost.Approved, Investigational
DelaprilTravoprost may increase the hypotensive activities of Delapril.Experimental
DeserpidineTravoprost may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Travoprost.Approved
DiclofenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiethylnorspermineTravoprost may increase the hypotensive activities of Diethylnorspermine.Investigational
DifenpiramideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe therapeutic efficacy of Travoprost can be decreased when used in combination with Diflunisal.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Travoprost.Investigational
DiltiazemTravoprost may increase the hypotensive activities of Diltiazem.Approved
DorzolamideTravoprost may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Travoprost.Approved
DroxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Droxicam.Withdrawn
DuvelisibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Travoprost can be decreased when used in combination with E-6201.Investigational
EfonidipineTravoprost may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilTravoprost may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTravoprost may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Travoprost.Experimental
EpanololTravoprost may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe therapeutic efficacy of Travoprost can be decreased when used in combination with Epirizole.Approved
EpoprostenolTravoprost may increase the hypotensive activities of Epoprostenol.Approved
EprosartanTravoprost may increase the hypotensive activities of Eprosartan.Approved
EtanerceptThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ethenzamide.Experimental
EtodolacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Travoprost can be decreased when used in combination with Evening primrose oil.Approved, Investigational
ExisulindThe therapeutic efficacy of Travoprost can be decreased when used in combination with Exisulind.Investigational
FelbinacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Felbinac.Experimental
FelodipineTravoprost may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Fenbufen.Approved
FenoldopamTravoprost may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ferulic acid.Experimental
FloctafenineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FlunixinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Flunoxaprofen.Experimental
FlurbiprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FosinoprilTravoprost may increase the hypotensive activities of Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Travoprost.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Travoprost can be decreased when used in combination with Guacetisal.Experimental
GuanabenzTravoprost may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Travoprost.Approved
GuanazodineTravoprost may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineTravoprost may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Travoprost.Approved, Investigational
GuanoclorTravoprost may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTravoprost may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTravoprost may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Travoprost.Experimental
HexamethoniumTravoprost may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Travoprost.Experimental
HydralazineHydralazine may increase the hypotensive activities of Travoprost.Approved
HydrochlorothiazideTravoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideTravoprost may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IbuprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Travoprost can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Travoprost.Approved, Investigational
ImidaprilTravoprost may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Imidazole salicylate.Experimental
IndapamideTravoprost may increase the hypotensive activities of Indapamide.Approved
IndenololTravoprost may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Travoprost.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Travoprost.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Travoprost.Withdrawn
IrbesartanTravoprost may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Travoprost.Approved
IsoxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Travoprost.Approved
KebuzoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Travoprost.Investigational
KetoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ketorolac.Approved
LabetalolTravoprost may increase the hypotensive activities of Labetalol.Approved
LacidipineTravoprost may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostTravoprost may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineTravoprost may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LinsidomineTravoprost may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilTravoprost may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lisofylline.Investigational
LofexidineTravoprost may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanTravoprost may increase the hypotensive activities of Losartan.Approved
LoxoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanTravoprost may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineTravoprost may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolThe therapeutic efficacy of Travoprost can be decreased when used in combination with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Travoprost.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Travoprost.Approved
Meclofenamic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Travoprost can be decreased when used in combination with Metamizole.Investigational, Withdrawn
MethoserpidineTravoprost may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaTravoprost may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Travoprost.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Travoprost.Approved, Investigational
MetipranololTravoprost may increase the hypotensive activities of Metipranolol.Approved
MetolazoneTravoprost may increase the hypotensive activities of Metolazone.Approved
MetoprololMetoprolol may increase the hypotensive activities of Travoprost.Approved, Investigational
MetyrosineTravoprost may increase the hypotensive activities of Metyrosine.Approved
MibefradilTravoprost may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Travoprost.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Travoprost.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Travoprost.Investigational
MizoribineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Travoprost.Approved
MoexiprilTravoprost may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Travoprost.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Travoprost.Approved, Investigational
MuzolimineTravoprost may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nabumetone.Approved
NadololTravoprost may increase the hypotensive activities of Nadolol.Approved
NafamostatThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Naftifine.Approved
NaftopidilTravoprost may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Naproxen.Approved, Vet Approved
NebivololTravoprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
NepafenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Travoprost.Withdrawn
NicardipineTravoprost may increase the hypotensive activities of Nicardipine.Approved
NicorandilTravoprost may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifenazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineTravoprost may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineTravoprost may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineTravoprost may increase the hypotensive activities of Nimodipine.Approved
NisoldipineTravoprost may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineTravoprost may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroaspirinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Travoprost.Approved
ObinutuzumabTravoprost may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Travoprost.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Travoprost.Approved, Investigational
OlopatadineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olsalazine.Approved
OmapatrilatTravoprost may increase the hypotensive activities of Omapatrilat.Investigational
OrgoteinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Orgotein.Vet Approved
OxaprozinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Oxaprozin.Approved
OxprenololTravoprost may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
ParecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Travoprost.Approved
ParthenolideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Parthenolide.Investigational
PenbutololTravoprost may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumTravoprost may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Travoprost.Approved, Investigational
PerindoprilTravoprost may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Travoprost.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Travoprost.Withdrawn
PhenoxybenzamineTravoprost may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Travoprost.Withdrawn
PhentolamineTravoprost may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Travoprost.Withdrawn
PindololTravoprost may increase the hypotensive activities of Pindolol.Approved
PirfenidoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Travoprost.Approved
PiroxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Travoprost.Withdrawn
Platelet Activating FactorTravoprost may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideTravoprost may increase the hypotensive activities of Polythiazide.Approved
PranoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Travoprost.Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Travoprost.Approved
ProglumetacinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Travoprost can be decreased when used in combination with Propacetamol.Approved, Investigational
PropranololTravoprost may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Proquazone.Experimental
PTC299The therapeutic efficacy of Travoprost can be decreased when used in combination with PTC299.Investigational
QuinaprilTravoprost may increase the hypotensive activities of Quinapril.Approved, Investigational
RamiprilRamipril may increase the hypotensive activities of Travoprost.Approved
RasagilineRasagiline may increase the hypotensive activities of Travoprost.Approved
RemikirenRemikiren may increase the hypotensive activities of Travoprost.Approved
RescinnamineTravoprost may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Travoprost.Approved, Investigational
ResveratrolThe therapeutic efficacy of Travoprost can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Travoprost.Investigational
RiociguatTravoprost may increase the hypotensive activities of Riociguat.Approved
RituximabTravoprost may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
SafrazineSafrazine may increase the hypotensive activities of Travoprost.Withdrawn
SalicylamideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salsalate.Approved
SaprisartanTravoprost may increase the hypotensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypotensive activities of Travoprost.Approved, Investigational, Vet Approved
SelexipagTravoprost may increase the hypotensive activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Travoprost can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Travoprost can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Travoprost can be decreased when used in combination with Serrapeptase.Investigational
SildenafilSildenafil may increase the antihypertensive activities of Travoprost.Approved, Investigational
SitaxentanTravoprost may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilTravoprost may increase the hypotensive activities of Spirapril.Approved
SRT501The therapeutic efficacy of Travoprost can be decreased when used in combination with SRT501.Investigational
SulfasalazineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Sulindac.Approved
SuprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Travoprost.Approved, Investigational
TalinololTravoprost may increase the hypotensive activities of Talinolol.Investigational
TarenflurbilThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanTravoprost may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilTravoprost may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Teriflunomide.Approved
TerlipressinTravoprost may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineTravoprost may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineTravoprost may increase the hypotensive activities of Theodrenaline.Investigational
Tiaprofenic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneTravoprost may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTravoprost may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTravoprost may increase the hypotensive activities of Timolol.Approved
TinoridineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tinoridine.Investigational
TolazolineTravoprost may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolmetin.Approved
TolonidineTravoprost may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Travoprost.Approved
TorasemideTorasemide may increase the hypotensive activities of Travoprost.Approved
TrandolaprilTravoprost may increase the hypotensive activities of Trandolapril.Approved
TranilastThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Travoprost.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Travoprost.Approved
TreprostinilTravoprost may increase the hypotensive activities of Treprostinil.Approved, Investigational
TribenosideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideTravoprost may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Travoprost.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Travoprost.Approved, Investigational
TriptolideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Triptolide.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Travoprost.Approved, Investigational
UnoprostoneTravoprost may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Travoprost.Investigational
ValdecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Travoprost.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Travoprost.Approved
VincamineTravoprost may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTravoprost may increase the hypotensive activities of Vinpocetine.Investigational
XipamideTravoprost may increase the hypotensive activities of Xipamide.Experimental
XylometazolineTravoprost may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Travoprost.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilTravoprost may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
  1. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763]
  2. Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. doi: 10.1517/14656560903300129. [PubMed:19929706]
  3. Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9. [PubMed:9038626]
  4. Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. doi: 10.1016/j.survophthal.2008.08.010. [PubMed:19038618]
  5. Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. doi: 10.1517/14740330802465474 . [PubMed:18983226]
External Links
Human Metabolome Database
HMDB14432
KEGG Drug
D01964
PubChem Compound
5282226
PubChem Substance
46507637
ChemSpider
4445407
ChEBI
746859
ChEMBL
CHEMBL1200799
Therapeutic Targets Database
DAP000274
PharmGKB
PA164781371
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Travoprost
ATC Codes
S01EE04 — Travoprost
AHFS Codes
  • 52:40.28 — Prostaglandin Analogs
FDA label
Download (36.8 KB)
MSDS
Download (72.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentGlaucoma / Ocular Hypertension1
2Active Not RecruitingTreatmentGlaucoma and Ocular Hypertension1
2CompletedTreatmentGlaucoma / Glaucoma or Ocular Hypertension and / Ocular Hypertension / Ocular Surface Disease1
2CompletedTreatmentGlaucoma / Ocular Hypertension2
2CompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)1
2CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)5
3CompletedTreatmentGlaucoma, Angle-Closure / Ocular Hypertension1
3CompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)1
3CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)11
3RecruitingPreventionGlaucoma1
3RecruitingTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)1
3TerminatedTreatmentGlaucoma / Ocular Hypertension2
3Unknown StatusTreatmentGlaucoma2
3WithdrawnTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)1
4Active Not RecruitingTreatmentOpen-angle Glaucoma (OAG)2
4CompletedSupportive CareDry Eye Syndrome (DES)1
4CompletedTreatmentAnterior Uveitis (AU) / Cystoid Macular Edema1
4CompletedTreatmentApplication Site Pigmentation Changes / Glaucoma1
4CompletedTreatmentGlaucoma5
4CompletedTreatmentGlaucoma, Angle-Closure1
4CompletedTreatmentGlaucoma / Ocular Hypertension9
4CompletedTreatmentGlaucoma / Ocular Hypertension / Open-angle Glaucoma (OAG)1
4CompletedTreatmentHyperemia / Intraocular Pressure1
4CompletedTreatmentIntraocular Pressure1
4CompletedTreatmentNormal Tension Glaucoma / Ocular Hypertension1
4CompletedTreatmentOcular Hypertension1
4CompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)3
4CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)5
4CompletedTreatmentOpen-angle Glaucoma (OAG)2
4Not Yet RecruitingTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
4RecruitingTreatmentGlaucoma1
4TerminatedNot AvailableOcular Hypertension / Open-angle Glaucoma (OAG)1
4TerminatedNot AvailableOpen-angle Glaucoma (OAG)1
4TerminatedTreatmentGlaucoma1
4TerminatedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
Not AvailableCompletedNot AvailableOcular Dryness / Ocular Hypertension / Ocular Irritation / Open-angle Glaucoma (OAG)1
Not AvailableCompletedNot AvailableOcular Hypertension / Open-angle Glaucoma (OAG)1
Not AvailableCompletedDiagnosticGlaucoma / Ocular Hypertension1
Not AvailableCompletedTreatmentGlaucoma, Primary Open Angle (POAG)1
Not AvailableCompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG) / Pseudoexfoliation Syndrome1
Not AvailableUnknown StatusTreatmentOcular Hypertension / Primary Glaucoma1
Not AvailableWithdrawnTreatmentGlaucoma, Neovascular1

Pharmacoeconomics

Manufacturers
  • Alcon inc
Packagers
Dosage forms
FormRouteStrength
SolutionOphthalmic0.003 %
Solution / dropsOphthalmic30 μg/ml
SolutionOphthalmic
SolutionOphthalmic0.004 %
Solution / dropsOphthalmic40 μg/ml
SolutionOphthalmic.04 mg/mL
Solution / dropsOphthalmic.04 mg/mL
Prices
Unit descriptionCostUnit
Travatan 0.004% Solution 5ml Bottle190.82USD bottle
Travatan Z 0.004% Solution 5ml Bottle190.82USD bottle
Travatan 0.004% Solution 2.5ml Bottle95.41USD bottle
Travatan Z 0.004% Solution 2.5ml Bottle95.41USD bottle
Travatan 0.004% eye drop45.87USD ml
Travatan z 0.004% eye drop36.7USD ml
Travatan 0.004 % Solution12.18USD ml
Travatan Z 0.004 % Solution12.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5631287No1994-12-222014-12-22Us
US6503497No1995-05-062012-05-06Us
CA2181172No2003-04-292015-12-19Canada
CA2129287No2002-05-142014-08-02Canada
US8268299No2009-10-132029-10-13Us
US8323630No2007-09-202027-09-20Us
US8388941No2007-09-202027-09-20Us
US9144561No2009-03-132029-03-13Us
US8722735No2009-10-102029-10-10Us
US8178582No2009-10-102029-10-10Us
US8754123No2009-05-192029-05-19Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
water solubility>16 mg/ml at 25.0°CNot Available
logP4.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00759 mg/mLALOGPS
logP4.02ALOGPS
logP3.84ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.95ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area96.22 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity127.86 m3·mol-1ChemAxon
Polarizability51.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9857
Blood Brain Barrier+0.887
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.5907
P-glycoprotein inhibitor INon-inhibitor0.8237
P-glycoprotein inhibitor IINon-inhibitor0.6435
Renal organic cation transporterNon-inhibitor0.8856
CYP450 2C9 substrateNon-substrate0.8327
CYP450 2D6 substrateNon-substrate0.8383
CYP450 3A4 substrateSubstrate0.652
CYP450 1A2 substrateNon-inhibitor0.728
CYP450 2C9 inhibitorNon-inhibitor0.7607
CYP450 2D6 inhibitorNon-inhibitor0.9125
CYP450 2C19 inhibitorNon-inhibitor0.6844
CYP450 3A4 inhibitorNon-inhibitor0.8546
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7657
Ames testNon AMES toxic0.7427
CarcinogenicityNon-carcinogens0.9088
BiodegradationNot ready biodegradable0.9726
Rat acute toxicity3.5280 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9744
hERG inhibition (predictor II)Non-inhibitor0.6722
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Eicosanoids
Direct Parent
Prostaglandins and related compounds
Alternative Parents
Trifluoromethylbenzenes / Phenoxy compounds / Phenol ethers / Fatty acid esters / Alkyl aryl ethers / Cyclopentanols / Cyclic alcohols and derivatives / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organofluorides
show 4 more
Substituents
Prostaglandin skeleton / Trifluoromethylbenzene / Phenoxy compound / Phenol ether / Alkyl aryl ether / Fatty acid ester / Monocyclic benzene moiety / Benzenoid / Cyclopentanol / Cyclic alcohol
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
carboxylic ester, prostaglandins Falpha, (trifluoromethyl)benzenes (CHEBI:746859)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Prostaglandin f receptor activity
Specific Function
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis...
Gene Name
PTGFR
Uniprot ID
P43088
Uniprot Name
Prostaglandin F2-alpha receptor
Molecular Weight
40054.1 Da
References
  1. Ota T, Aihara M, Narumiya S, Araie M: The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63. [PubMed:16249494]
  2. Thieme H, Schimmat C, Munzer G, Boxberger M, Fromm M, Pfeiffer N, Rosenthal R: Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):938-45. [PubMed:16505027]
  3. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763]
  4. Neacsu AM: [Receptors involved in the mechanism of action of topical prostaglandines]. Oftalmologia. 2009;53(2):3-7. [PubMed:19697832]
  5. Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. doi: 10.1517/14656560903300129. [PubMed:19929706]
  6. Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9. [PubMed:9038626]
  7. Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. doi: 10.1016/j.survophthal.2008.08.010. [PubMed:19038618]
  8. Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. doi: 10.1517/14740330802465474 . [PubMed:18983226]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on January 14, 2018 10:04